Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTerpath-012: V940 + pembrolizumab versus placebo + pembrolizumab in first-line advanced melanoma
MOH_2025-04-24_014051Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in melanoma comparing V940 + pembrolizumab with Placebo + pembrolizumab (2 arms). Primary endpoint: Progression-free survival. Started Apr 2025; status: recruiting.
02
Drugs
intismeran autogenepembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on MOH_2025-04-24_014051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-04-24_014051.